High-frequency nausea was more common in females than males (adjusted
odds ratio 1.35, 95% confidence interval 1.26-1.44). Persons with high-frequency nausea, compared with the no/rare or less than half the time nausea groups, reported significantly more headache symptoms and more headache-related impact as measured by the Headache Impact Test-6. High-frequency nausea was also associated with being occupationally disabled or on medical leave, and more self-reported financial burden of headache medications, worry about running out of headache medication(s), and that headache medications interfered with work or school work, household LY294002 work, and family/leisure activities. Regression-based correlational analyses indicated that nausea contributes significantly and independently to headache-related impact. High-frequency migraine-associated nausea is common and is a marker for severe, debilitating migraine. Nausea makes an independent contribution to migraine-associated disability and impact. Management strategies that take nausea into account could reduce the burden of migraine. Nausea is an important target for monitoring and treatment. “
“Astellas Pharma, Chicago, IL, USA To investigate the factors that influence a migraineur’s beliefs regarding oral triptans for RXDX-106 the acute treatment of migraines and to provide further insight into patients’ decision-making process when faced with migraine.
A multicenter, cross-sectional, observational study of subjects currently prescribed an oral triptan medication for the acute treatment of migraine headaches. Subjects were recruited from 6 headache clinics and one primary care practice in the United States. Enrolled subjects completed a questionnaire that could be completed either at the site as part of the visit or at home. The questionnaire comprised 27 questions assessing demographic find more characteristics, migraine history, migraine frequency and severity, and general beliefs about migraine treatments. The study population was stratified into 2 cohorts (Early Treatment and Delayed Treatment)
based on how they typically use their oral triptan to treat a typical migraine. A total 506 subjects were enrolled in the study, of which 502 were stratified into the Early Treatment cohort (41.2%) and Delayed Treatment cohort (58.8%). Demographic and clinical characteristics were generally similar between the 2 cohorts. In terms of general treatment patterns, there were notable differences between the Delayed and Early Treatment cohorts, with the Delayed Treatment cohort significantly more likely to take an over-the-counter (OTC) or non-triptan medication first (P ≤ .001) and only take a triptan if the OTC or non-triptan medication did not work (P ≤ .001). Furthermore, 55% of the Delayed Treatment cohort delayed taking a triptan to be certain that the headache was a migraine (vs 32% of the Early Treatment cohort; P ≤ .001).